The contract modifications are for Emergent’s current ten-year contracts with the US Department of Health and Human Services. Image Credit: Images Products / Shutterstock.

Emergent BioSolutions has received contract modifications worth more than $250m from the US Department of Health and Human Services (HHS) to supply “millions of doses” of four medical countermeasures (MCMs).

The US Department of HHS Administration for Strategic Preparedness and Response (ASPR) edited existing contracts with Emergent to ensure “continued supply/stockpiling of critical MCMs to address biological threats and emergencies against anthrax, smallpox and botulism”.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The two MCMs under the contract modifications include Emergent’s adjuvanted anthrax post-exposure prophylaxis vaccine Cyfendus, and ACAM2000, a live smallpox vaccine. The contract modification for Cyfendus was valued at $30m and ACAM2000 at $99.9m.

Emergent also signed two new contract options for VIGIV [vaccinia immune globulin intravenous] products for treating smallpox vaccination complications and BAT (botulism antitoxin heptavalent), a treatment for symptomatic botulism. The new options are valued at $122.9m and are part of the company’s existing ten-year contracts with ASPR.

The increased vaccine supply could be attributed to an increase in smallpox / mpox cases over the past year. It has also resulted in an increased demand for vaccines in multiple countries as part of their public preparedness actions.

See Also:

Following the news, Emergent saw a modest upswing in its stock, which was up by 6% when the market closed on 2 July, compared to the market close on the previous day. The company’s market cap stands at $392.49m.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The news comes two months after the company started its cost-saving plans, which included firing around 300 employees and making approximately 85 positions redundant. This was in line with Emergent’s plan to solely focus on its medical countermeasures and Narcan operations.

Emergent has several contracts with government agencies for vaccines and therapeutics for infectious diseases. In January, the company signed a $235.8m contract with the US Department of Defence to supply Cyfendus.

Cyfendus is an adsorbed form of the anthrax vaccine packaged along with an adjuvant. It was approved for post-exposure prophylaxis use in adults aged 18 – 65 years by the US Food and Drug Administration (FDA) in 2023. The two-dose anthrax vaccine is meant to be administered in conjunction with recommended antibacterial drugs by the FDA.

In August 2023, Emergent signed a ten-year contract worth up to $704m to develop Ebanga (ansuvimab-zykl) for the Biomedical Advanced Research and Development Authority (BARDA), which is part of ASPR. Ebanga is a monoclonal antibody that was approved by the FDA to treat the Ebola virus disease in 2020.